ArticlePituitary2014
Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche?
Article in Pituitary, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.Neurosurgical review · 2020Pooled it
- Laser microdissection-based multi-omics integration unveils the pathological atlas and tumor differentiation network of adamantinomatous craniopharyngioma.Acta neuropathologica communications · 2026Article
- Finger-like protrusions in adamantinomatous craniopharyngiomas: implications for recurrence and prognosis following complete tumor resection and predictive factors.Neurosurgical review · 2025Article
- Predictive Factors for Pediatric Craniopharyngioma Recurrence: An Extensive Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Molecular biological features of cyst wall of adamantinomatous craniopharyngioma.Scientific reports · 2023Article
- Exploring the pathological relationships between adamantinomatous craniopharyngioma and contiguous structures with tumor origin.Journal of neuro-oncology · 2022Article
- Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.Frontiers in endocrinology · 2022Article
- Treatment of Cystic Craniopharyngiomas: An Update.Advances and technical standards in neurosurgery · 2022Article
- Establishing a papillary craniopharyngioma cell line by SV40LT-mediated immortalization.Pituitary · 2021Article
- Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.International medical case reports journal · 2020Article
- Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.Endocrine-related cancer · 2019Article
- Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.Pituitary · 2018Review
- Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.Neuro-oncology · 2018Article
- Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.Journal of neurological surgery. Part B, Skull base · 2018Review
- Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma.Nature communications · 2017Article
- Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue.Scientific reports · 2017Article
- Can recurrences be predicted in craniopharyngiomas? β-catenin coexisting with stem cells markers and p-ATM in a clinicopathologic study of 45cases.Journal of experimental & clinical cancer research : CR · 2017Article
- Genetically engineered mouse models of craniopharyngioma: an opportunity for therapy development and understanding of tumor biology.Brain pathology (Zurich, Switzerland) · 2017Review
- Models of human adamantinomatous craniopharyngioma tissue: Steps toward an effective adjuvant treatment.Brain pathology (Zurich, Switzerland) · 2017Article
- Recent advances in molecular pathology of craniopharyngioma.F1000Research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEarly disease onset, clinical manifestation, histomorphology, and increased tendency to relapse distinguish the adamantinomatous craniopharyngioma (adaCP) from the more favorable papillary variant (papCP). A molecular hallmark of adaCP is the activated Wnt signaling pathway indicated by nuclear β-catenin accumulation in a subset of tumor cells. A mouse model recently illustrated that these cells are the driving force in tumorigenesis of adaCP. This observation and the peculiar growth pattern points to the existence of a specific tumor stem cell (TSC) population in human CP. MATERIALS AND
methodsTo prove this hypothesis, the TSC markers CD133 (Prominin1) and CD44 were examined in papCP (n = 8) and adaCP (n = 25) on mRNA level using quantitative real time PCR of total tumor RNA. Furthermore, we investigated protein expression performing immunohistochemical analyses of formalin-fixed paraffin embedded tumor samples.
resultsPapCP revealed a homogenous CD44 expression pattern predominantly at the cell membrane, whereas CD133 labeling was hardly detectable. In adaCP, on the other hand all markers were consistently and predominantly co-expressed in nuclear β-catenin accumulating cell clusters, which was confirmed by double immunofluorescence staining. Overall expression of CD44 was significantly decreased in adaCP versus papCP, whereas CD133 showed significantly higher protein and mRNA levels in adaCP.
conclusionsOur results indicate tumor stem cell-like characteristics of β-catenin accumulating cell clusters in adaCP, which may represent a tumor stem cell niche and might contribute to tumor recurrence. The potential impact of these special cell groups in regard to future CP management, including postoperative follow-up and additional treatment remains to be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.